News Alnylam plunges after deaths in rare disease trial Biotech axes revusiran due to safety concerns.
News Patients may have quit statins after media row Coverage may have given "disproportional weight" to concerns over side effects.
News Teva walks away from Mesoblast's heart failure drug Mesoblast to continue developing stem cell based therapy.
News Victoza disappoints on cardio benefits, lifts rival Jardianc... Victoza results are significant, but fell short of investors' expectations.
News Threat of Trump's pharma tariffs looms again The Trump administration is said to be preparing to announce tariffs of up to 100% on some pharmaceutical imports.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
